CareDx, Inc. (NASDAQ:CDNA) Director Sells $185,800.00 in Stock

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Peter Maag sold 10,000 shares of CareDx stock in a transaction on Monday, July 7th. The stock was sold at an average price of $18.58, for a total transaction of $185,800.00. Following the sale, the director owned 308,846 shares in the company, valued at $5,738,358.68. This represents a 3.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Peter Maag also recently made the following trade(s):

• On Tuesday, June 17th, Peter Maag sold 10,000 shares of CareDx stock. The stock was sold at an average price of $19.24, for a total transaction of $192,400.00.
• On Wednesday, April 30th, Peter Maag sold 13,281 shares of CareDx stock. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63.

CareDx Stock Performance

Shares of NASDAQ:CDNA traded down $0.50 on Friday, hitting $20.13. The stock had a trading volume of 1,339,105 shares, compared to its average volume of 926,356. CareDx, Inc. has a twelve month low of $14.09 and a twelve month high of $34.84. The firm's 50 day moving average price is $18.09 and its 200-day moving average price is $19.70. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of 17.50 and a beta of 2.19.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The firm's quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) EPS. As a group, sell-side analysts predict that CareDx, Inc. will post -0.9 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. HC Wainwright reiterated a "neutral" rating and set a $25.00 price target on shares of CareDx in a research note on Monday, May 5th. Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Stephens restated an "overweight" rating and issued a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. Finally, The Goldman Sachs Group reduced their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, CareDx currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC lifted its position in CareDx by 12.8% during the 1st quarter. Voya Investment Management LLC now owns 24,400 shares of the company's stock worth $433,000 after buying an additional 2,761 shares in the last quarter. Strs Ohio acquired a new position in CareDx during the 1st quarter worth about $462,000. Acadian Asset Management LLC boosted its holdings in CareDx by 6.1% in the first quarter. Acadian Asset Management LLC now owns 359,303 shares of the company's stock valued at $6,373,000 after acquiring an additional 20,806 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in CareDx by 11.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company's stock valued at $2,378,000 after acquiring an additional 13,619 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in CareDx by 18.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company's stock worth $19,703,000 after purchasing an additional 170,504 shares during the last quarter.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.